Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease

We aimed to identify genetic variants associated with heart failure by using a rat model of the human disease. We performed invasive cardiac hemodynamic measurements in F2 crosses between spontaneously hypertensive heart failure (SHHF) rats and reference strains. We combined linkage analyses with genome-wide expression profiling and identified Ephx2 as a heart failure susceptibility gene in SHHF rats. Specifically, we found that cis variation at Ephx2 segregated with heart failure and with increased transcript expression, protein expression and enzyme activity, leading to a more rapid hydrolysis of cardioprotective epoxyeicosatrienoic acids. To confirm our results, we tested the role of Ephx2 in heart failure using knockout mice. Ephx2 gene ablation protected from pressure overload–induced heart failure and cardiac arrhythmias. We further demonstrated differential regulation of EPHX2 in human heart failure, suggesting a cross-species role for Ephx2 in this complex disease.

[1]  M. Corretti,et al.  Cellular mechanisms of altered contractility in the hypertrophied heart: big hearts, big sparks. , 1999, Circulation Research.

[2]  D. Kelly,et al.  Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. , 1996, Circulation.

[3]  Andrew I Su,et al.  Uncovering regulatory pathways that affect hematopoietic stem cell function using 'genetical genomics' , 2005, Nature Genetics.

[4]  B. Hammock,et al.  Hydration of an 18O epoxide by a cytosolic epoxide hydrolase from mouse liver. , 1980, Life sciences.

[5]  B. Dahlöf,et al.  Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) , 1991, The Lancet.

[6]  L. Kruglyak,et al.  Genetic Dissection of Transcriptional Regulation in Budding Yeast , 2002, Science.

[7]  J. Ornato,et al.  ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .

[8]  E. Petretto,et al.  Integrated transcriptional profiling and linkage analysis for identification of genes underlying disease , 2005, Nature Genetics.

[9]  Karl Swedberg,et al.  Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients , 2005, Circulation.

[10]  Xiao-Ping Yang,et al.  Increased Systolic Performance With Diastolic Dysfunction in Adult Spontaneously Hypertensive Rats , 2003, Hypertension.

[11]  Robert W. Williams,et al.  Complex trait analysis of gene expression uncovers polygenic and pleiotropic networks that modulate nervous system function , 2005, Nature Genetics.

[12]  J. Foley,et al.  Enhanced Postischemic Functional Recovery in CYP2J2 Transgenic Hearts Involves Mitochondrial ATP-Sensitive K+ Channels and p42/p44 MAPK Pathway , 2004, Circulation research.

[13]  E. Olson,et al.  Hypertrophy of the heart: a new therapeutic target? , 2004, Circulation.

[14]  G. Dorn,et al.  Cytoplasmic signaling pathways that regulate cardiac hypertrophy. , 2001, Annual review of physiology.

[15]  Yi Fu,et al.  Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo , 2007, Proceedings of the National Academy of Sciences.

[16]  D. Levy,et al.  Association of parental heart failure with risk of heart failure in offspring. , 2006, The New England journal of medicine.

[17]  E. Blasi,et al.  Structural, functional, and molecular characterization of the SHHF model of heart failure. , 2002, American journal of physiology. Heart and circulatory physiology.

[18]  C. Molony,et al.  Genetic analysis of genome-wide variation in human gene expression , 2004, Nature.

[19]  J. Liao,et al.  Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. , 2005, Archives of biochemistry and biophysics.

[20]  R. Stoughton,et al.  Genetics of gene expression surveyed in maize, mouse and man , 2003, Nature.

[21]  Nature Genetics , 1991, Nature.

[22]  K. Chien.  Genomic circuits and the integrative biology of cardiac diseases , 2000, Nature.

[23]  B. Hammock,et al.  Soluble Epoxide Hydrolase Inhibition Lowers Arterial Blood Pressure in Angiotensin II Hypertension , 2002, Hypertension.

[24]  A J Belanger,et al.  Epidemiology of heart failure. , 1991, American heart journal.

[25]  Edward D Frohlich,et al.  Long-term left ventricular echocardiographic follow-up of SHR and WKY rats: effects of hypertension and age. , 2004, American journal of physiology. Heart and circulatory physiology.

[26]  B. Hammock,et al.  Compensatory Mechanism for Homeostatic Blood Pressure Regulation in Ephx2 Gene-disrupted Mice* , 2007, Journal of Biological Chemistry.

[27]  J. Seidman,et al.  The Genetic Basis for Cardiomyopathy from Mutation Identification to Mechanistic Paradigms , 2001, Cell.

[28]  B. Hammock,et al.  Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors , 2006, Proceedings of the National Academy of Sciences.

[29]  B Buis,et al.  Continuous measurement of left ventricular volume in animals and humans by conductance catheter. , 1984, Circulation.

[30]  Martin Farrall,et al.  Genetic susceptibility to coronary artery disease: from promise to progress , 2006, Nature Reviews Genetics.

[31]  A. Lee,et al.  Regulation of the rat CYP4A2 gene promoter by c-Jun and octamer binding protein-1. , 2007, The international journal of biochemistry & cell biology.

[32]  Gary Peltz,et al.  In Silico Genetics: Identification of a Functional Element Regulating H2-Eα Gene Expression , 2004, Science.

[33]  B. Davis,et al.  Prevention of Heart Failure by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension , 1997 .

[34]  Kai Stühler,et al.  Genetic analysis of the mouse brain proteome , 2002, Nature Genetics.

[35]  Daniel Levy,et al.  Long-term trends in the incidence of and survival with heart failure. , 2002, The New England journal of medicine.

[36]  M. Blaufox,et al.  Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. , 1997, JAMA.

[37]  J. Falck,et al.  Role of Soluble Epoxide Hydrolase in Postischemic Recovery of Heart Contractile Function , 2006, Circulation research.

[38]  G. Peltz,et al.  In Silico Mapping of Complex Disease-Related Traits in Mice , 2001, Science.

[39]  S. Mccune,et al.  Plasma renin activity in heart failure-prone SHHF/Mcc-facp rats. , 1997, The American journal of physiology.

[40]  D E Grobbee,et al.  The epidemiology of heart failure. , 1997, European heart journal.

[41]  E. Antman,et al.  ACC/AHA PRACTICE GUIDELINES ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary , 2002 .

[42]  R. Kloner,et al.  Transthoracic echocardiography in rats Evalution of commonly used indices of left ventricular dimensions, contractile performance, and hypertrophy in a genetic model of hypertrophic heart failure (SHHF-Mcc-facp-Rats) in comparison with Wistar rats during aging , 2003, Basic Research in Cardiology.

[43]  S. Mccune,et al.  Myocardial tumor necrosis factor-α secretion in hypertensive and heart failure-prone rats. , 1999, American journal of physiology. Heart and circulatory physiology.

[44]  Xiang Fang,et al.  Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. , 2004, Progress in lipid research.

[45]  Jens Jordan,et al.  Autonomic nervous system and blood pressure regulation in RGS2-deficient mice. , 2005, American journal of physiology. Regulatory, integrative and comparative physiology.

[46]  C. Angermann,et al.  Sustained activation of nuclear factor kappa B and activator protein 1 in chronic heart failure. , 2003, Cardiovascular research.

[47]  J. Imig.  Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors. , 2006, Cardiovascular drug reviews.

[48]  M. Pfeffer,et al.  Hemodynamic and Myocardial Function in Young and Old Normotensive and Spontaneously Hypertensive Rats , 1973, Circulation research.

[49]  V. Roger,et al.  Trends in prevalence and outcome of heart failure with preserved ejection fraction. , 2006, The New England journal of medicine.

[50]  E. Schadt,et al.  Genetic inheritance of gene expression in human cell lines. , 2004, American journal of human genetics.

[51]  G. Peltz,et al.  Identification of complement factor 5 as a susceptibility locus for experimental allergic asthma , 2000, Nature Immunology.

[52]  P. Baker,et al.  SHHF/Mcc-cp Rat: Model of Obesity, Non-insulin-dependent Diabetes, and Congestive Heart Failure , 1990 .

[53]  W. Birchmeier,et al.  &bgr;-Catenin Downregulation Is Required for Adaptive Cardiac Remodeling , 2007, Circulation research.